Predictive Oncology (NASDAQ:POAI) Stock Passes Below 200-Day Moving Average – Here’s Why

Predictive Oncology Inc. (NASDAQ:POAI)’s share price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.08 and traded as low as $0.73. Predictive Oncology shares last traded at $0.79, with a volume of 76,521 shares.

Wall Street Analyst Weigh In

Separately, HC Wainwright began coverage on Predictive Oncology in a research report on Monday, August 19th. They set a “buy” rating and a $3.00 target price on the stock.

Predictive Oncology Trading Down 1.6 %

The stock has a 50 day moving average of $0.76 and a 200-day moving average of $1.08. The company has a market capitalization of $5.25 million, a P/E ratio of -0.23 and a beta of 1.14.

Predictive Oncology (NASDAQ:POAI) last posted its quarterly earnings results on Tuesday, August 13th. The medical instruments supplier reported ($0.68) earnings per share for the quarter. The firm had revenue of $0.28 million during the quarter. Predictive Oncology had a negative return on equity of 200.06% and a negative net margin of 802.69%. As a group, sell-side analysts expect that Predictive Oncology Inc. will post -2.03 EPS for the current fiscal year.

Predictive Oncology Company Profile

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.